Comparing First-line Natalizumab and Ocrelizumab Use for the Treatment of Multiple Sclerosis: A Komodo Health Claims Database Study (P7-1.012)
To compare the difference of post-treatment initiation relapse outcomes as well as non-disease-modifying therapy (DMT) healthcare resource utilization (HCRU) and healthcare costs (HCC), in patients with multiple sclerosis (MS) who were treated with first-line natalizumab (NTZ, TYSABRI®) or ocrelizumab (OCR).
Authors
- Martin Belkin
- Jeffrey Kaplan (ORCID: https://orcid.org/0000-0001-9531-7825)
- Nicholas Belviso
- David Ni
- Danette Rutledge
- Heidi Crayton (ORCID: https://orcid.org/0009-0008-6785-8155)
- Christopher Eckstein (ORCID: https://orcid.org/0000-0003-0732-3972)
- Boyang Bian (ORCID: https://orcid.org/0000-0003-0153-4218)
- Dana Beenstock
- Ruth Fredericks
Institutions
- Biogen (United States) (US)
- Duke University (US)
- Michigan Institute for Neurological Disorders (US)
- Washington Center (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211891
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00